APO Research
Talk to an analyst

APO RESEARCH · REPORT

Imatinib Mesylate API

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Imatinib Mesylate API Market Outlook and Growth Opportunities 2026

23 December 2025207 pages

Choose your research edition.

Industry ResearchImatinib Mesylate API Industry Research Report 2026137 pages · $2,950 USDIndustry Growth & TrendsGlobal Imatinib Mesylate API Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Imatinib Mesylate API Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Imatinib Mesylate API Market Outlook and Growth Opportunities 2026207 pages · $4,250 USDMarket Analysis & ForecastGlobal Imatinib Mesylate API Market Analysis and Forecast 2026-2032207 pages · $4,950 USD

Market perspective

The global Imatinib Mesylate API market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Imatinib Mesylate API is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Imatinib Mesylate API is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Imatinib Mesylate API is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Imatinib Mesylate API market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Imatinib Mesylate API market include Zhejiang Jiuzhou Pharmaceutical Co Ltd, Sun Pharma, Shanghai Yuanye Bio-Technology, Shandong Anxin Pharmaceutical Co Ltd, Mylan, Zydus Lifesciences Ltd, Zydus Lifesciences, Sun Pharmaceutical Industries Ltd and Shilpa Pharma Lifesciences Ltd, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Imatinib Mesylate API market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Imatinib Mesylate API and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Imatinib Mesylate API sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Imatinib Mesylate API market size, projected growth trends, production technologies, key applications, and end-use industries.

Imatinib Mesylate API Segment by Company

Zhejiang Jiuzhou Pharmaceutical Co Ltd

Sun Pharma

Shanghai Yuanye Bio-Technology

Shandong Anxin Pharmaceutical Co Ltd

Mylan

Zydus Lifesciences Ltd

Zydus Lifesciences

Sun Pharmaceutical Industries Ltd

Shilpa Pharma Lifesciences Ltd

Natco Pharma Ltd

Msn Laboratories Private Ltd

Laurus Labs Ltd

Intas Pharmaceuticals Ltd

Hetero Labs Ltd

Dr. Reddy’s

Cipla Ltd

Aurobindo Pharma Ltd

Acebright India Pharma Private Ltd

Imatinib Mesylate API Segment by Type

Purity ≥ 98%

Purity < 98%

Imatinib Mesylate API Segment by Application

Chronic Myeloid Leukemia (CML)

Gastrointestinal Stromal Tumor (GIST)

Others

Imatinib Mesylate API Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Imatinib Mesylate API status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Imatinib Mesylate API market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Imatinib Mesylate API significant trends, drivers, influence factors in global and regions.

6. To analyze Imatinib Mesylate API competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Imatinib Mesylate API market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Imatinib Mesylate API and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Imatinib Mesylate API.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Imatinib Mesylate API market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Imatinib Mesylate API industry.

Chapter 3: Detailed analysis of Imatinib Mesylate API manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Imatinib Mesylate API in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Imatinib Mesylate API in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Imatinib Mesylate API Industry Trends Table 2. Imatinib Mesylate API Industry Drivers Table 3. Imatinib Mesylate API Industry Opportunities and Challenges Table 4. Imatinib Mesylate API Industry Restraints Table 5. Global Imatinib Mesylate API Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Imatinib Mesylate API Revenue Share by Company (2021-2026) Table 7. Global Imatinib Mesylate API Sales Volume by Company (kg) & (2021-2026) Table 8. Global Imatinib Mesylate API Sales Volume Share by Company (2021-2026) Table 9. Global Imatinib Mesylate API Average Price (USD/g) of Company (2021-2026) Table 10. Global Imatinib Mesylate API Company Ranking, (2024-2026) & (USD Million) Table 11. Global Imatinib Mesylate API Key Company Manufacturing Base & Headquarters Table 12. Global Imatinib Mesylate API Company, Product Type & Application Table 13. Global Imatinib Mesylate API Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Imatinib Mesylate API by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Purity ≥ 98% Table 18. Significant Companies of Purity < 98% Table 19. Global Imatinib Mesylate API Sales Volume by Type 2021 VS 2025 VS 2032 (kg) Table 20. Global Imatinib Mesylate API Sales Volume by Type (2021-2026) & (kg) Table 21. Global Imatinib Mesylate API Sales Volume by Type (2027-2032) & (kg) Table 22. Global Imatinib Mesylate API Sales Volume Share by Type (2021-2026) Table 23. Global Imatinib Mesylate API Sales Volume Share by Type (2027-2032) Table 24. Global Imatinib Mesylate API Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Imatinib Mesylate API Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Imatinib Mesylate API Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Imatinib Mesylate API Sales Value Share by Type (2021-2026) Table 28. Global Imatinib Mesylate API Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Chronic Myeloid Leukemia (CML) Table 30. Significant Companies of Gastrointestinal Stromal Tumor (GIST) Table 31. Significant Companies of Others Table 32. Global Imatinib Mesylate API Sales Volume by Application 2021 VS 2025 VS 2032 (kg) Table 33. Global Imatinib Mesylate API Sales Volume by Application (2021-2026) & (kg) Table 34. Global Imatinib Mesylate API Sales Volume by Application (2027-2032) & (kg) Table 35. Global Imatinib Mesylate API Sales Volume Share by Application (2021-2026) Table 36. Global Imatinib Mesylate API Sales Volume Share by Application (2027-2032) Table 37. Global Imatinib Mesylate API Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Imatinib Mesylate API Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Imatinib Mesylate API Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Imatinib Mesylate API Sales Value Share by Application (2021-2026) Table 41. Global Imatinib Mesylate API Sales Value Share by Application (2027-2032) Table 42. Global Imatinib Mesylate API Sales by Region: 2021 VS 2025 VS 2032 (kg) Table 43. Global Imatinib Mesylate API Sales by Region (2021-2026) & (kg) Table 44. Global Imatinib Mesylate API Sales Market Share by Region (2021-2026) Table 45. Global Imatinib Mesylate API Sales by Region (2027-2032) & (kg) Table 46. Global Imatinib Mesylate API Sales Market Share by Region (2027-2032) Table 47. Global Imatinib Mesylate API Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Imatinib Mesylate API Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Imatinib Mesylate API Sales Value Share by Region (2021-2026) Table 50. Global Imatinib Mesylate API Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Imatinib Mesylate API Sales Value Share by Region (2027-2032) Table 52. Global Imatinib Mesylate API Market Average Price (USD/g) by Region (2021-2026) Table 53. Global Imatinib Mesylate API Market Average Price (USD/g) by Region (2027-2032) Table 54. Global Imatinib Mesylate API Sales by Country: 2021 VS 2025 VS 2032 (kg) Table 55. Global Imatinib Mesylate API Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Imatinib Mesylate API Sales by Country (2021-2026) & (kg) Table 57. Global Imatinib Mesylate API Sales Market Share by Country (2021-2026) Table 58. Global Imatinib Mesylate API Sales by Country (2027-2032) & (kg) Table 59. Global Imatinib Mesylate API Sales Market Share by Country (2027-2032) Table 60. Global Imatinib Mesylate API Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Imatinib Mesylate API Sales Value Market Share by Country (2021-2026) Table 62. Global Imatinib Mesylate API Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Imatinib Mesylate API Sales Value Market Share by Country (2027-2032) Table 64. Zhejiang Jiuzhou Pharmaceutical Co Ltd Company Information Table 65. Zhejiang Jiuzhou Pharmaceutical Co Ltd Business Overview Table 66. Zhejiang Jiuzhou Pharmaceutical Co Ltd Imatinib Mesylate API Sales (kg), Value (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 67. Zhejiang Jiuzhou Pharmaceutical Co Ltd Imatinib Mesylate API Product Portfolio Table 68. Zhejiang Jiuzhou Pharmaceutical Co Ltd Recent Development Table 69. Sun Pharma Company Information Table 70. Sun Pharma Business Overview Table 71. Sun Pharma Imatinib Mesylate API Sales (kg), Value (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 72. Sun Pharma Imatinib Mesylate API Product Portfolio Table 73. Sun Pharma Recent Development Table 74. Shanghai Yuanye Bio-Technology Company Information Table 75. Shanghai Yuanye Bio-Technology Business Overview Table 76. Shanghai Yuanye Bio-Technology Imatinib Mesylate API Sales (kg), Value (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 77. Shanghai Yuanye Bio-Technology Imatinib Mesylate API Product Portfolio Table 78. Shanghai Yuanye Bio-Technology Recent Development Table 79. Shandong Anxin Pharmaceutical Co Ltd Company Information Table 80. Shandong Anxin Pharmaceutical Co Ltd Business Overview Table 81. Shandong Anxin Pharmaceutical Co Ltd Imatinib Mesylate API Sales (kg), Value (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 82. Shandong Anxin Pharmaceutical Co Ltd Imatinib Mesylate API Product Portfolio Table 83. Shandong Anxin Pharmaceutical Co Ltd Recent Development Table 84. Mylan Company Information Table 85. Mylan Business Overview Table 86. Mylan Imatinib Mesylate API Sales (kg), Value (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 87. Mylan Imatinib Mesylate API Product Portfolio Table 88. Mylan Recent Development Table 89. Zydus Lifesciences Ltd Company Information Table 90. Zydus Lifesciences Ltd Business Overview Table 91. Zydus Lifesciences Ltd Imatinib Mesylate API Sales (kg), Value (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 92. Zydus Lifesciences Ltd Imatinib Mesylate API Product Portfolio Table 93. Zydus Lifesciences Ltd Recent Development Table 94. Zydus Lifesciences Company Information Table 95. Zydus Lifesciences Business Overview Table 96. Zydus Lifesciences Imatinib Mesylate API Sales (kg), Value (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 97. Zydus Lifesciences Imatinib Mesylate API Product Portfolio Table 98. Zydus Lifesciences Recent Development Table 99. Sun Pharmaceutical Industries Ltd Company Information Table 100. Sun Pharmaceutical Industries Ltd Business Overview Table 101. Sun Pharmaceutical Industries Ltd Imatinib Mesylate API Sales (kg), Value (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 102. Sun Pharmaceutical Industries Ltd Imatinib Mesylate API Product Portfolio Table 103. Sun Pharmaceutical Industries Ltd Recent Development Table 104. Shilpa Pharma Lifesciences Ltd Company Information Table 105. Shilpa Pharma Lifesciences Ltd Business Overview Table 106. Shilpa Pharma Lifesciences Ltd Imatinib Mesylate API Sales (kg), Value (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 107. Shilpa Pharma Lifesciences Ltd Imatinib Mesylate API Product Portfolio Table 108. Shilpa Pharma Lifesciences Ltd Recent Development Table 109. Natco Pharma Ltd Company Information Table 110. Natco Pharma Ltd Business Overview Table 111. Natco Pharma Ltd Imatinib Mesylate API Sales (kg), Value (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 112. Natco Pharma Ltd Imatinib Mesylate API Product Portfolio Table 113. Natco Pharma Ltd Recent Development Table 114. Msn Laboratories Private Ltd Company Information Table 115. Msn Laboratories Private Ltd Business Overview Table 116. Msn Laboratories Private Ltd Imatinib Mesylate API Sales (kg), Value (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 117. Msn Laboratories Private Ltd Imatinib Mesylate API Product Portfolio Table 118. Msn Laboratories Private Ltd Recent Development Table 119. Laurus Labs Ltd Company Information Table 120. Laurus Labs Ltd Business Overview Table 121. Laurus Labs Ltd Imatinib Mesylate API Sales (kg), Value (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 122. Laurus Labs Ltd Imatinib Mesylate API Product Portfolio Table 123. Laurus Labs Ltd Recent Development Table 124. Intas Pharmaceuticals Ltd Company Information Table 125. Intas Pharmaceuticals Ltd Business Overview Table 126. Intas Pharmaceuticals Ltd Imatinib Mesylate API Sales (kg), Value (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 127. Intas Pharmaceuticals Ltd Imatinib Mesylate API Product Portfolio Table 128. Intas Pharmaceuticals Ltd Recent Development Table 129. Hetero Labs Ltd Company Information Table 130. Hetero Labs Ltd Business Overview Table 131. Hetero Labs Ltd Imatinib Mesylate API Sales (kg), Value (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 132. Hetero Labs Ltd Imatinib Mesylate API Product Portfolio Table 133. Hetero Labs Ltd Recent Development Table 134. Dr. Reddy’s Company Information Table 135. Dr. Reddy’s Business Overview Table 136. Dr. Reddy’s Imatinib Mesylate API Sales (kg), Value (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 137. Dr. Reddy’s Imatinib Mesylate API Product Portfolio Table 138. Dr. Reddy’s Recent Development Table 139. Cipla Ltd Company Information Table 140. Cipla Ltd Business Overview Table 141. Cipla Ltd Imatinib Mesylate API Sales (kg), Value (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 142. Cipla Ltd Imatinib Mesylate API Product Portfolio Table 143. Cipla Ltd Recent Development Table 144. Aurobindo Pharma Ltd Company Information Table 145. Aurobindo Pharma Ltd Business Overview Table 146. Aurobindo Pharma Ltd Imatinib Mesylate API Sales (kg), Value (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 147. Aurobindo Pharma Ltd Imatinib Mesylate API Product Portfolio Table 148. Aurobindo Pharma Ltd Recent Development Table 149. Acebright India Pharma Private Ltd Company Information Table 150. Acebright India Pharma Private Ltd Business Overview Table 151. Acebright India Pharma Private Ltd Imatinib Mesylate API Sales (kg), Value (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 152. Acebright India Pharma Private Ltd Imatinib Mesylate API Product Portfolio Table 153. Acebright India Pharma Private Ltd Recent Development Table 154. Key Raw Materials Table 155. Raw Materials Key Suppliers Table 156. Imatinib Mesylate API Distributors List Table 157. Imatinib Mesylate API Customers List Table 158. Research Programs/Design for This Report Table 159. Authors List of This Report Table 160. Secondary Sources Table 161. Primary Sources List of Figures Figure 1. Imatinib Mesylate API Product Image Figure 2. Global Imatinib Mesylate API Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Imatinib Mesylate API Sales Value (2021-2032) & (US$ Million) Figure 4. Global Imatinib Mesylate API Sales (2021-2032) & (kg) Figure 5. Global Imatinib Mesylate API Sales Average Price (USD/g) & (2021-2032) Figure 6. Global Imatinib Mesylate API Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Purity ≥ 98% Image Figure 10. Purity < 98% Image Figure 11. Global Imatinib Mesylate API Sales Volume by Type (2021 VS 2025 VS 2032) & (kg) Figure 12. Global Imatinib Mesylate API Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Imatinib Mesylate API Sales Volume Share by Type (2021-2032) Figure 14. Global Imatinib Mesylate API Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Imatinib Mesylate API Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Imatinib Mesylate API Sales Value Share by Type (2021-2032) Figure 17. Chronic Myeloid Leukemia (CML) Image Figure 18. Gastrointestinal Stromal Tumor (GIST) Image Figure 19. Others Image Figure 20. Global Imatinib Mesylate API Sales Volume by Application (2021 VS 2025 VS 2032) & (kg) Figure 21. Global Imatinib Mesylate API Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Imatinib Mesylate API Sales Volume Share by Application (2021-2032) Figure 23. Global Imatinib Mesylate API Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Imatinib Mesylate API Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Imatinib Mesylate API Sales Value Share by Application (2021-2032) Figure 26. Global Imatinib Mesylate API Sales by Region: 2021 VS 2025 VS 2032 (kg) Figure 27. Global Imatinib Mesylate API Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Imatinib Mesylate API Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Imatinib Mesylate API Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Imatinib Mesylate API Sales Value (2021-2032) & (US$ Million) Figure 31. North America Imatinib Mesylate API Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Imatinib Mesylate API Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Imatinib Mesylate API Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Imatinib Mesylate API Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Imatinib Mesylate API Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Imatinib Mesylate API Sales Value (2021-2032) & (US$ Million) Figure 37. South America Imatinib Mesylate API Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Imatinib Mesylate API Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Imatinib Mesylate API Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Imatinib Mesylate API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Imatinib Mesylate API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Imatinib Mesylate API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Imatinib Mesylate API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Imatinib Mesylate API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Imatinib Mesylate API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Imatinib Mesylate API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Imatinib Mesylate API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Imatinib Mesylate API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Imatinib Mesylate API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Imatinib Mesylate API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Imatinib Mesylate API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Imatinib Mesylate API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Imatinib Mesylate API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Imatinib Mesylate API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Imatinib Mesylate API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Imatinib Mesylate API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Imatinib Mesylate API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Imatinib Mesylate API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Imatinib Mesylate API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Imatinib Mesylate API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Imatinib Mesylate API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Imatinib Mesylate API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Imatinib Mesylate API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Imatinib Mesylate API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Imatinib Mesylate API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Imatinib Mesylate API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Imatinib Mesylate API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Imatinib Mesylate API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Imatinib Mesylate API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Imatinib Mesylate API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Imatinib Mesylate API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Imatinib Mesylate API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Imatinib Mesylate API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Imatinib Mesylate API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Imatinib Mesylate API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Imatinib Mesylate API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Imatinib Mesylate API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Imatinib Mesylate API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Imatinib Mesylate API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Imatinib Mesylate API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Imatinib Mesylate API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Imatinib Mesylate API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Imatinib Mesylate API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Imatinib Mesylate API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Imatinib Mesylate API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Imatinib Mesylate API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Imatinib Mesylate API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Imatinib Mesylate API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Imatinib Mesylate API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Imatinib Mesylate API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Imatinib Mesylate API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Imatinib Mesylate API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Imatinib Mesylate API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Imatinib Mesylate API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Imatinib Mesylate API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Imatinib Mesylate API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Imatinib Mesylate API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Imatinib Mesylate API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Imatinib Mesylate API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Imatinib Mesylate API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Imatinib Mesylate API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Imatinib Mesylate API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Imatinib Mesylate API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Imatinib Mesylate API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Imatinib Mesylate API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Imatinib Mesylate API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Imatinib Mesylate API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Imatinib Mesylate API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Imatinib Mesylate API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Imatinib Mesylate API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Imatinib Mesylate API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Imatinib Mesylate API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Imatinib Mesylate API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Imatinib Mesylate API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Imatinib Mesylate API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Imatinib Mesylate API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Imatinib Mesylate API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Imatinib Mesylate API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Imatinib Mesylate API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Imatinib Mesylate API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Imatinib Mesylate API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Imatinib Mesylate API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Imatinib Mesylate API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Imatinib Mesylate API Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Imatinib Mesylate API Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Purity ≥ 98%
  • Purity < 98%
Applications
  • Chronic Myeloid Leukemia (CML)
  • Gastrointestinal Stromal Tumor (GIST)
  • Others
Companies covered
  • Zhejiang Jiuzhou Pharmaceutical Co Ltd
  • Sun Pharma
  • Shanghai Yuanye Bio-Technology
  • Shandong Anxin Pharmaceutical Co Ltd
  • Mylan
  • Zydus Lifesciences Ltd
  • Zydus Lifesciences
  • Sun Pharmaceutical Industries Ltd
  • Shilpa Pharma Lifesciences Ltd
  • Natco Pharma Ltd
  • Msn Laboratories Private Ltd
  • Laurus Labs Ltd
  • Intas Pharmaceuticals Ltd
  • Hetero Labs Ltd
  • Dr. Reddy’s
  • Cipla Ltd
  • Aurobindo Pharma Ltd
  • Acebright India Pharma Private Ltd

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Imatinib Mesylate API Sales Value (2021-2032)
  4. 1.2.2 Global Imatinib Mesylate API Sales Volume (2021-2032)
  5. 1.2.3 Global Imatinib Mesylate API Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Imatinib Mesylate API Market Dynamics
  1. 2.1 Imatinib Mesylate API Industry Trends
  2. 2.2 Imatinib Mesylate API Industry Drivers
  3. 2.3 Imatinib Mesylate API Industry Opportunities and Challenges
  4. 2.4 Imatinib Mesylate API Industry Restraints
3 Imatinib Mesylate API Market by Company
  1. 3.1 Global Imatinib Mesylate API Company Revenue Ranking in 2025
  2. 3.2 Global Imatinib Mesylate API Revenue by Company (2021-2026)
  3. 3.3 Global Imatinib Mesylate API Sales Volume by Company (2021-2026)
  4. 3.4 Global Imatinib Mesylate API Average Price by Company (2021-2026)
  5. 3.5 Global Imatinib Mesylate API Company Ranking (2024-2026)
  6. 3.6 Global Imatinib Mesylate API Company Manufacturing Base and Headquarters
  7. 3.7 Global Imatinib Mesylate API Company Product Type and Application
  8. 3.8 Global Imatinib Mesylate API Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Imatinib Mesylate API Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Imatinib Mesylate API Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Imatinib Mesylate API Market by Type
  1. 4.1 Imatinib Mesylate API Type Introduction
  2. 4.1.1 Purity ≥ 98%
  3. 4.1.2 Purity < 98%
  4. 4.2 Global Imatinib Mesylate API Sales Volume by Type
  5. 4.2.1 Global Imatinib Mesylate API Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Imatinib Mesylate API Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Imatinib Mesylate API Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Imatinib Mesylate API Sales Value by Type
  9. 4.3.1 Global Imatinib Mesylate API Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Imatinib Mesylate API Sales Value by Type (2021-2032)
  11. 4.3.3 Global Imatinib Mesylate API Sales Value Share by Type (2021-2032)
5 Imatinib Mesylate API Market by Application
  1. 5.1 Imatinib Mesylate API Application Introduction
  2. 5.1.1 Chronic Myeloid Leukemia (CML)
  3. 5.1.2 Gastrointestinal Stromal Tumor (GIST)
  4. 5.1.3 Others
  5. 5.2 Global Imatinib Mesylate API Sales Volume by Application
  6. 5.2.1 Global Imatinib Mesylate API Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Imatinib Mesylate API Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Imatinib Mesylate API Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Imatinib Mesylate API Sales Value by Application
  10. 5.3.1 Global Imatinib Mesylate API Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Imatinib Mesylate API Sales Value by Application (2021-2032)
  12. 5.3.3 Global Imatinib Mesylate API Sales Value Share by Application (2021-2032)
6 Imatinib Mesylate API Regional Sales and Value Analysis
  1. 6.1 Global Imatinib Mesylate API Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Imatinib Mesylate API Sales by Region (2021-2032)
  3. 6.2.1 Global Imatinib Mesylate API Sales by Region: 2021-2026
  4. 6.2.2 Global Imatinib Mesylate API Sales by Region (2027-2032)
  5. 6.3 Global Imatinib Mesylate API Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Imatinib Mesylate API Sales Value by Region (2021-2032)
  7. 6.4.1 Global Imatinib Mesylate API Sales Value by Region: 2021-2026
  8. 6.4.2 Global Imatinib Mesylate API Sales Value by Region (2027-2032)
  9. 6.5 Global Imatinib Mesylate API Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Imatinib Mesylate API Sales Value (2021-2032)
  12. 6.6.2 North America Imatinib Mesylate API Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Imatinib Mesylate API Sales Value (2021-2032)
  15. 6.7.2 Europe Imatinib Mesylate API Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Imatinib Mesylate API Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Imatinib Mesylate API Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Imatinib Mesylate API Sales Value (2021-2032)
  21. 6.9.2 South America Imatinib Mesylate API Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Imatinib Mesylate API Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Imatinib Mesylate API Sales Value Share by Country, 2025 VS 2032
7 Imatinib Mesylate API Country-level Sales and Value Analysis
  1. 7.1 Global Imatinib Mesylate API Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Imatinib Mesylate API Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Imatinib Mesylate API Sales by Country (2021-2032)
  4. 7.3.1 Global Imatinib Mesylate API Sales by Country (2021-2026)
  5. 7.3.2 Global Imatinib Mesylate API Sales by Country (2027-2032)
  6. 7.4 Global Imatinib Mesylate API Sales Value by Country (2021-2032)
  7. 7.4.1 Global Imatinib Mesylate API Sales Value by Country (2021-2026)
  8. 7.4.2 Global Imatinib Mesylate API Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Imatinib Mesylate API Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Imatinib Mesylate API Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Imatinib Mesylate API Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Imatinib Mesylate API Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Imatinib Mesylate API Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Imatinib Mesylate API Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Imatinib Mesylate API Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Imatinib Mesylate API Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Imatinib Mesylate API Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Imatinib Mesylate API Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Imatinib Mesylate API Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Imatinib Mesylate API Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Imatinib Mesylate API Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Imatinib Mesylate API Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Imatinib Mesylate API Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Imatinib Mesylate API Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Imatinib Mesylate API Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Imatinib Mesylate API Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Imatinib Mesylate API Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Imatinib Mesylate API Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Imatinib Mesylate API Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Imatinib Mesylate API Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Imatinib Mesylate API Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Imatinib Mesylate API Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Imatinib Mesylate API Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Imatinib Mesylate API Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Imatinib Mesylate API Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Imatinib Mesylate API Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Imatinib Mesylate API Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Imatinib Mesylate API Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Imatinib Mesylate API Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Imatinib Mesylate API Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Imatinib Mesylate API Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Imatinib Mesylate API Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Imatinib Mesylate API Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Imatinib Mesylate API Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Imatinib Mesylate API Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Imatinib Mesylate API Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Imatinib Mesylate API Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Imatinib Mesylate API Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Imatinib Mesylate API Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Imatinib Mesylate API Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Imatinib Mesylate API Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Imatinib Mesylate API Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Imatinib Mesylate API Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Imatinib Mesylate API Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Imatinib Mesylate API Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Imatinib Mesylate API Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Imatinib Mesylate API Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Imatinib Mesylate API Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Imatinib Mesylate API Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Imatinib Mesylate API Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Imatinib Mesylate API Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Imatinib Mesylate API Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Imatinib Mesylate API Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Imatinib Mesylate API Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Imatinib Mesylate API Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Imatinib Mesylate API Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Imatinib Mesylate API Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Imatinib Mesylate API Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Imatinib Mesylate API Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Imatinib Mesylate API Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Imatinib Mesylate API Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Imatinib Mesylate API Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Imatinib Mesylate API Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Imatinib Mesylate API Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Imatinib Mesylate API Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Imatinib Mesylate API Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Imatinib Mesylate API Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Imatinib Mesylate API Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Imatinib Mesylate API Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Imatinib Mesylate API Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Imatinib Mesylate API Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Imatinib Mesylate API Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Imatinib Mesylate API Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Imatinib Mesylate API Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Imatinib Mesylate API Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Imatinib Mesylate API Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Imatinib Mesylate API Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Imatinib Mesylate API Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Imatinib Mesylate API Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Imatinib Mesylate API Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Imatinib Mesylate API Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Imatinib Mesylate API Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Zhejiang Jiuzhou Pharmaceutical Co Ltd
  2. 8.1.1 Zhejiang Jiuzhou Pharmaceutical Co Ltd Company Information
  3. 8.1.2 Zhejiang Jiuzhou Pharmaceutical Co Ltd Business Overview
  4. 8.1.3 Zhejiang Jiuzhou Pharmaceutical Co Ltd Imatinib Mesylate API Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Zhejiang Jiuzhou Pharmaceutical Co Ltd Imatinib Mesylate API Product Portfolio
  6. 8.1.5 Zhejiang Jiuzhou Pharmaceutical Co Ltd Recent Developments
  7. 8.2 Sun Pharma
  8. 8.2.1 Sun Pharma Company Information
  9. 8.2.2 Sun Pharma Business Overview
  10. 8.2.3 Sun Pharma Imatinib Mesylate API Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Sun Pharma Imatinib Mesylate API Product Portfolio
  12. 8.2.5 Sun Pharma Recent Developments
  13. 8.3 Shanghai Yuanye Bio-Technology
  14. 8.3.1 Shanghai Yuanye Bio-Technology Company Information
  15. 8.3.2 Shanghai Yuanye Bio-Technology Business Overview
  16. 8.3.3 Shanghai Yuanye Bio-Technology Imatinib Mesylate API Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Shanghai Yuanye Bio-Technology Imatinib Mesylate API Product Portfolio
  18. 8.3.5 Shanghai Yuanye Bio-Technology Recent Developments
  19. 8.4 Shandong Anxin Pharmaceutical Co Ltd
  20. 8.4.1 Shandong Anxin Pharmaceutical Co Ltd Company Information
  21. 8.4.2 Shandong Anxin Pharmaceutical Co Ltd Business Overview
  22. 8.4.3 Shandong Anxin Pharmaceutical Co Ltd Imatinib Mesylate API Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Shandong Anxin Pharmaceutical Co Ltd Imatinib Mesylate API Product Portfolio
  24. 8.4.5 Shandong Anxin Pharmaceutical Co Ltd Recent Developments
  25. 8.5 Mylan
  26. 8.5.1 Mylan Company Information
  27. 8.5.2 Mylan Business Overview
  28. 8.5.3 Mylan Imatinib Mesylate API Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Mylan Imatinib Mesylate API Product Portfolio
  30. 8.5.5 Mylan Recent Developments
  31. 8.6 Zydus Lifesciences Ltd
  32. 8.6.1 Zydus Lifesciences Ltd Company Information
  33. 8.6.2 Zydus Lifesciences Ltd Business Overview
  34. 8.6.3 Zydus Lifesciences Ltd Imatinib Mesylate API Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Zydus Lifesciences Ltd Imatinib Mesylate API Product Portfolio
  36. 8.6.5 Zydus Lifesciences Ltd Recent Developments
  37. 8.7 Zydus Lifesciences
  38. 8.7.1 Zydus Lifesciences Company Information
  39. 8.7.2 Zydus Lifesciences Business Overview
  40. 8.7.3 Zydus Lifesciences Imatinib Mesylate API Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Zydus Lifesciences Imatinib Mesylate API Product Portfolio
  42. 8.7.5 Zydus Lifesciences Recent Developments
  43. 8.8 Sun Pharmaceutical Industries Ltd
  44. 8.8.1 Sun Pharmaceutical Industries Ltd Company Information
  45. 8.8.2 Sun Pharmaceutical Industries Ltd Business Overview
  46. 8.8.3 Sun Pharmaceutical Industries Ltd Imatinib Mesylate API Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Sun Pharmaceutical Industries Ltd Imatinib Mesylate API Product Portfolio
  48. 8.8.5 Sun Pharmaceutical Industries Ltd Recent Developments
  49. 8.9 Shilpa Pharma Lifesciences Ltd
  50. 8.9.1 Shilpa Pharma Lifesciences Ltd Company Information
  51. 8.9.2 Shilpa Pharma Lifesciences Ltd Business Overview
  52. 8.9.3 Shilpa Pharma Lifesciences Ltd Imatinib Mesylate API Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Shilpa Pharma Lifesciences Ltd Imatinib Mesylate API Product Portfolio
  54. 8.9.5 Shilpa Pharma Lifesciences Ltd Recent Developments
  55. 8.10 Natco Pharma Ltd
  56. 8.10.1 Natco Pharma Ltd Company Information
  57. 8.10.2 Natco Pharma Ltd Business Overview
  58. 8.10.3 Natco Pharma Ltd Imatinib Mesylate API Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Natco Pharma Ltd Imatinib Mesylate API Product Portfolio
  60. 8.10.5 Natco Pharma Ltd Recent Developments
  61. 8.11 Msn Laboratories Private Ltd
  62. 8.11.1 Msn Laboratories Private Ltd Company Information
  63. 8.11.2 Msn Laboratories Private Ltd Business Overview
  64. 8.11.3 Msn Laboratories Private Ltd Imatinib Mesylate API Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Msn Laboratories Private Ltd Imatinib Mesylate API Product Portfolio
  66. 8.11.5 Msn Laboratories Private Ltd Recent Developments
  67. 8.12 Laurus Labs Ltd
  68. 8.12.1 Laurus Labs Ltd Company Information
  69. 8.12.2 Laurus Labs Ltd Business Overview
  70. 8.12.3 Laurus Labs Ltd Imatinib Mesylate API Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Laurus Labs Ltd Imatinib Mesylate API Product Portfolio
  72. 8.12.5 Laurus Labs Ltd Recent Developments
  73. 8.13 Intas Pharmaceuticals Ltd
  74. 8.13.1 Intas Pharmaceuticals Ltd Company Information
  75. 8.13.2 Intas Pharmaceuticals Ltd Business Overview
  76. 8.13.3 Intas Pharmaceuticals Ltd Imatinib Mesylate API Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Intas Pharmaceuticals Ltd Imatinib Mesylate API Product Portfolio
  78. 8.13.5 Intas Pharmaceuticals Ltd Recent Developments
  79. 8.14 Hetero Labs Ltd
  80. 8.14.1 Hetero Labs Ltd Company Information
  81. 8.14.2 Hetero Labs Ltd Business Overview
  82. 8.14.3 Hetero Labs Ltd Imatinib Mesylate API Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Hetero Labs Ltd Imatinib Mesylate API Product Portfolio
  84. 8.14.5 Hetero Labs Ltd Recent Developments
  85. 8.15 Dr. Reddy’s
  86. 8.15.1 Dr. Reddy’s Company Information
  87. 8.15.2 Dr. Reddy’s Business Overview
  88. 8.15.3 Dr. Reddy’s Imatinib Mesylate API Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Dr. Reddy’s Imatinib Mesylate API Product Portfolio
  90. 8.15.5 Dr. Reddy’s Recent Developments
  91. 8.16 Cipla Ltd
  92. 8.16.1 Cipla Ltd Company Information
  93. 8.16.2 Cipla Ltd Business Overview
  94. 8.16.3 Cipla Ltd Imatinib Mesylate API Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Cipla Ltd Imatinib Mesylate API Product Portfolio
  96. 8.16.5 Cipla Ltd Recent Developments
  97. 8.17 Aurobindo Pharma Ltd
  98. 8.17.1 Aurobindo Pharma Ltd Company Information
  99. 8.17.2 Aurobindo Pharma Ltd Business Overview
  100. 8.17.3 Aurobindo Pharma Ltd Imatinib Mesylate API Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Aurobindo Pharma Ltd Imatinib Mesylate API Product Portfolio
  102. 8.17.5 Aurobindo Pharma Ltd Recent Developments
  103. 8.18 Acebright India Pharma Private Ltd
  104. 8.18.1 Acebright India Pharma Private Ltd Company Information
  105. 8.18.2 Acebright India Pharma Private Ltd Business Overview
  106. 8.18.3 Acebright India Pharma Private Ltd Imatinib Mesylate API Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 Acebright India Pharma Private Ltd Imatinib Mesylate API Product Portfolio
  108. 8.18.5 Acebright India Pharma Private Ltd Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Imatinib Mesylate API Value Chain Analysis
  2. 9.1.1 Imatinib Mesylate API Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Imatinib Mesylate API Sales Mode & Process
  6. 9.2 Imatinib Mesylate API Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Imatinib Mesylate API Distributors
  9. 9.2.3 Imatinib Mesylate API Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst